Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 155 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
2. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
3. Cita con resumen
Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]
4. Cita con resumen
Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]
5. Cita con resumen
Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]
6. Cita con resumen
Garattini S, Bertele V. Rosiglitazone and the need for a new drug safety agency. BMJ 2010;341:781-2. [Ref.ID 89479]
7. Cita con resumen
McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials 2010;13:11-37. [Ref.ID 88544]
8. Cita con resumen
Abecia Inchaurregui LC, Abasolo Osinaga E, Etxeandia Ikobaltzeta I, Burgos Alonso N, López Picado A, Fernández Bilbao M. Evolución de la utilización de hipolipemiantes en la comunidad autónoma del País Vasco (1992-2005). Aten Farmaceutica 2009;11:361-7. [Ref.ID 87455]
9.Enlace a cita original
García del Pozo J, Madurga M, de Abajo FJ. Utilización de hipolipemiantes en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86460]
10. Cita con resumen
Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109. [Ref.ID 84984]
11. Cita con resumen
Klotz U. Drug-related risks. Eur J Clin Pharmacol 2007;63:983-4. [Ref.ID 81426]
12. Cita con resumen
Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]
13.Enlace a cita original Cita con resumen
Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y. When good drugs go bad. Nature 2007;446:26 de abril. [Ref.ID 80079]
14.
Anónimo. Neuropathies périphériques et statines. Prescrire 2007;27:269-70. [Ref.ID 79734]
15. Cita con resumen
McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007;16:132-43. [Ref.ID 79332]
16. Cita con resumen
Motola D, Vargiu A, Leone R, Cocci A, Salvo F, Ros B, Meneghelli I, Venegoni M, Cutroneo PM, Vaccheri A, Velo G, Montanaro N. Hepatic adverse drug reactions: a case/non-case study in Italy. Eur J Clin Pharmacol 2007;63:73-9. [Ref.ID 79050]
17. Cita con resumen
Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11. [Ref.ID 78930]
18. Cita con resumen
Anónimo. Fewer than 30 Lipobay cases can still be settled, Bayer claims. Scrip 2006;3215:14. [Ref.ID 78651]
19.Tiene citas relacionadas Cita con resumen
Avorn J. Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med 2006;355:2169-71. [Ref.ID 78556]
Seleccionar todas
 
 1 a 20 de 155 siguiente >>